Chai Discovery closes $400M Series C at $3.8B; AI antibody design now used by Lilly, Pfizer, Novartis
Chai Discovery, a two-year-old AI drug-discovery startup, closed a $400 million Series C on July 14, 2026, valuing the company at $3.8 billion—nearly triple its $1.3 billion valuation seven months prior in December 2025 (Series B). The round was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension. Existing backers OpenAI and Thrive Capital also participated, along with new investors including Bain Capital Ventures, Battery Ventures, and Baillie Gifford. The raise brings Chai's total funding above $600 million in roughly 11 months.
Chai designs generative AI models for fully de novo antibody and molecular design, addressing "undruggable" targets that traditional discovery methods have failed. Its latest model, Chai-3, achieved material improvements in target success rates and binding affinity. Chai-2, released in 2025, was the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates—a 100-fold improvement over prior computational methods. Eli Lilly, Pfizer, and Novartis are now using Chai's models in production research pipelines, validating the move from academic promise to pharma deployment.
For R&D teams at large pharma, Chai's commercial traction signals that AI is no longer a proof-of-concept layer but a core discovery asset competing directly with lead-generation timelines. The company's Series C valuation near $4 billion is no longer outlier noise—it reflects genuine pharmaceutical customer validation and the market's pricing of compression in drug development timelines. Architects building biotech platforms should track Chai's model velocity (three generations in 18 months) and customer adoption rate (three pharma giants) as early signals of whether AI-driven molecular design is becoming a fixed part of the R&D stack.
Sources
- Primary source
- Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer
“Chai Discovery has continued its whirlwind emergence, closing its third financing round in less than a year to bring its total funding haul above $600 million. The latest round values the startup at $3.8 billion.”
- Chai Discovery gets $400M, tripling valuation from seven months ago
“One of the hottest startups in the AI-generated drug discovery landscape has corralled $400 million in a Series C that triples its paper value from its last round of financing.”
- Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design
“Chai-2, released in 2025, was the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates, representing a step-change over prior computational methods.”